AACI Update | October 2020

Headlines

Annual Meeting Spotlight: Basic Science and Pediatric Cancer Care

Annual Meeting Spotlight: Basic Science and Pediatric Cancer Care

The 2020 AACI/CCAF Annual Meeting will virtually convene AACI cancer center members with national cancer research and advocacy groups, industry, and government health agencies on October 12-13. At two meeting sessions, panelists will discuss the application of basic science and pediatric cancer research to the delivery of improved treatments for all cancers.  

Read More

AACI to Welcome New Members to CRI and GR Steering Committees

This fall, AACI will welcome new members to its Clinical Research Innovation (CRI) and Government Relations (GR) Forum steering committees. The new members will formally assume their duties during the 2020 AACI/CCAF Annual Meeting, held virtually October 12-13.
 

Read More

AACI Now Accepting Recommendations for PCLI Steering Committee

AACI Now Accepting Recommendations for PCLI Steering Committee

AACI is seeking recommendations for the Physician Clinical Leadership Initiative (PCLI) Steering Committee. The PCLI steering committee helps guide the activities of the initiative, identify barriers and challenges where AACI cancer center clinical leaders can share best practices, and identify ways AACI can collaborate with like-minded organizations.

Read More

News from the Centers

Schwarz Elected Officer of Radiation Research Society

Schwarz Elected Officer of Radiation Research Society
Siteman Cancer Center

Julie K. Schwarz, MD, PhD, a Washington University professor of radiation oncology at Siteman Cancer Center, has been elected vice president of the Radiation Research Society. She will go on to serve as president beginning in October 2022.

Read More

Farma Recognized as Master Surgeon Educator

Farma Recognized as Master Surgeon Educator
Fox Chase Cancer Center, Temple Health

Fox Chase Cancer Center’s Jeffrey Farma, MD, FACS, was recently admitted to the American College of Surgeons Academy of Master Surgeon Educators. He is chief of the Division of General Surgery at Fox Chase and co-director of the Melanoma and Skin Cancer Program.

Read More

5 For the Fight Announces Inaugural Class of Fellows

Huntsman Cancer Institute, University of Utah

5 For the Fight, a global movement inviting everyone to give $5 for the fight against cancer, has announced the inaugural recipients of the 5 For the Fight Cancer Research Fellowship in partnership with Huntsman Cancer Institute at the University of Utah.

Read More

Martin Awarded New Endowed Professorship

Martin Awarded New Endowed Professorship
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

Breast cancer researcher Stuart S. Martin, PhD, has been installed as the inaugural Drs. Angela and Harry Brodie Professor in Translational Cancer Research. The endowed professorship honors the late Angela H. Brodie, PhD, who, with her husband, Harry Brodie, PhD, pioneered the development of aromatase inhibitors.

Read More

Back to News From the Centers

Sylvester Receives Landmark $126 Million Gift

Sylvester Receives Landmark $126 Million Gift
Sylvester Comprehensive Cancer Center, University of Miami Health System

A landmark gift of $126 million to the Sylvester Comprehensive Cancer Center at the University of Miami Leonard M. Miller School of Medicine will accelerate advances in finding cures for cancer and expand treatment options for patients. The anonymous donation, made in honor of Sylvester Director Stephen D. Nimer, MD, is the largest in the University of Miami’s 95-year history.

Read More

$111 Million NIH Grant Awarded to Prevent and Treat HIV-Associated Cancers

$111 Million NIH Grant Awarded to Prevent and Treat HIV-Associated Cancers
Albert Einstein Cancer Center, Albert Einstein College of Medicine

For 25 years, the AIDS Malignancy Consortium has led national and international efforts to prevent and treat of HIV-related cancers. Now, Montefiore Health System and Albert Einstein College of Medicine have received a five-year, $111 million grant from the National Cancer Institute to lead this research consortium. Joseph Sparano, MD, is principal investigator on the grant.

Read More

'Exceptional' Score Earned With NCI-Designated Comprehensive Center Renewal

'Exceptional' Score Earned With NCI-Designated Comprehensive Center Renewal
Vanderbilt-Ingram Cancer Center

Vanderbilt-Ingram Cancer Center (VICC) has received an overall "exceptional" score from the National Cancer Institute (NCI) for its research impact and patient care excellence. The center's renewal of its NCI Cancer Center Support Grant provides more than $36 million in funding over the next five years. This is VICC's fifth overall renewal and third with Jennifer Pietenpol, PhD, as the center's director.

Read More

Tisch Gets Second Consecutive NCI Designation

Tisch Gets Second Consecutive NCI Designation
The Tisch Cancer Institute at Mount Sinai

The Tisch Cancer Institute at Mount Sinai has been awarded $13 million as part of the renewal of its National Cancer Institute cancer center designation. The funding complements $53 million in current cancer research grants. Ramon Parsons, MD, PhD, is the center's director.

Read More

Effort to Combat Melanoma Gets $13 Million Boost

UCLA Jonsson Comprehensive Cancer Center

UCLA researchers have received a $13 million grant from the National Institutes of Health to find new ways to overcome melanoma resistance to some of the most promising targeted therapies and immunotherapies.

Read More

NIH Funds Research on Differences in Glioblastoma Between Males, Females

Case Comprehensive Cancer Center

A Case Comprehensive Cancer Center-led team has secured $10.4 million over five years from the National Institutes of Health/National Cancer Institute to explore at the molecular level the differences in glioblastoma between males and females.

Read More

Ohio State to Study Impact of COVID-19 in First Responders With $10 Million Grant

The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Researchers at The Ohio State University College of Medicine and The Ohio State University Wexner Medical Center have been awarded a five-year, $10 million grant from the National Cancer Institute to study the long-term, longitudinal impact of COVID-19 on first responders, health care workers, and the general population.

Read More

$5.7 Million Awarded to Study Chemo-Induced Hearing Loss, Toxicities

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Lois B. Travis, MD, ScD, at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, has been awarded a five-year, $5.7 million National Cancer Institute grant to evaluate long-term health outcomes for cancer patients who receive platinum-based chemotherapies.

Read More

$3.7 Million Awarded to Address Genetic Testing Among Families

University of Michigan Rogel Cancer Center

A $3.7 million grant, part of the Beau Biden Cancer Moonshot Initiative, will support a clinical trial designed to test a personalized family genetic risk navigation support platform. The trial will be extended to all first- and second-degree relatives of 900 patients in Georgia and California in whom genetic testing identified a variant indicating an elevated hereditary cancer risk.

Read More

$3.1 Million Grant Supports Exploration of Immune Response to Cancer Mutations

Rutgers Cancer Institute of New Jersey

With the aid of a $3.1 million, five-year National Institutes of Health grant, Rutgers Cancer Institute of New Jersey leaders Eileen White, PhD, Edmund Lattime, PhD, and Shridar Ganesan, MD, PhD, will collaborate on translational research exploring the immune response to cancers that feature a high number of mutations.

Read More

Fighting Breast Cancer With Nanotech, Immunotherapy

Case Comprehensive Cancer Center

Efstathios "Stathis” Karathanasis, PhD and William Schiemann, PhD are leading a team of researchers from the Case Comprehensive Cancer Center and Duke University combining nanotechnology with immunotherapy to treat metastatic breast cancer. The team received a five-year, $3 million grant from the National Cancer Institute to continue research into the engineering of nanoparticles that can wake up "cold" tumors so they can be located and attacked by the immune system.

Read More

$2.9 Million Grant Will Look at Impact of HPV on Head and Neck Cancer

$2.9 Million Grant Will Look at Impact of HPV on Head and Neck Cancer
University of Michigan Rogel Cancer Center

Researchers from the Rogel Cancer Center have received a $2.9 million grant from the National Cancer Institute to look at how HPV behaves in patients with head and neck cancer and how that could help identify who might benefit from less aggressive treatment. Principal investigator is Maureen Sartor, PhD.

Read More

$1.9 Million Grant Funds DNA Damage Research

UAMS Winthrop P. Rockefeller Cancer Institute

A $1.9 million grant from the National Institute of General Medical Studies will allow Justin Leung, Ph.D., at the University of Arkansas for Medical Sciences, to advance his research of DNA damage response in cancer and genetic disorders.

Read More

Grant to Fund Gene Imaging Research

Yale Cancer Center, Yale School of Medicine

The National Institutes of Health has awarded an Exploratory/Developmental Research Grant to fund 3D gene imaging research at Yale Cancer Center. The three-year, $1.2 million R33 award will help support research on multiplexed imaging of chromatin folding and RNA profiles in cancer and lead to new biomarkers for cancer diagnosis, prognosis, and treatment. 

Read More

$1.1 Million Grant Awarded to Develop Metabolomics Data Analysis Tools

UK Markey Cancer Center

The National Science Foundation has awarded a three-year, $1,163,869 grant to the University of Kentucky to develop state-of-the-art metabolomics data analysis tools that will derive new data, knowledge, and interpretation from the active metabolic state of organisms and ecosystems with broad biological and biomedical applications.

Read More

Back to News From the Centers

Osborne Steps Down as Director

Osborne Steps Down as Director
Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine

After 15 years in the role, C. Kent Osborne, MD, has stepped down as director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine. He will stay on at Baylor as founding director of the center. Helen Heslop, MD, DSc (Hon), director of the Center for Cell and Gene Therapy, will serve as interim director.

Read More

Gruber to Head Center for Precision Medicine

Gruber to Head Center for Precision Medicine
City of Hope Comprehensive Cancer Center

Cancer geneticist Stephen Gruber, MD, PhD, MPH, has joined City of Hope as the director of its newly founded Center for Precision Medicine. He will lead a team of more than 14 researchers who will work across the institution to pioneer personalized cancer prevention and treatment plans.

Read More

Patel Appointed as Caspar Wistar Fellow

Patel Appointed as Caspar Wistar Fellow
The Wistar Institute

The Wistar Institute has appointed Ami Patel, PhD, as a Caspar Wistar Fellow in the Vaccine and Immunotherapy Center. Her research focuses on strategies to combat emerging infectious diseases, including engineering vaccines and immunotherapies against viral and bacterial pathogens. 

Read More

Expert in Early-Phase Cancer Research Tapped to Head Clinical Investigation Team

Expert in Early-Phase Cancer Research Tapped to Head Clinical Investigation Team
Roswell Park Comprehensive Cancer Center

Having dedicated his career to developing better treatments for cancer, Roswell Park Comprehensive Cancer Center’s Igor Puzanov, MD, MSCI, FACP, has been promoted to senior vice president of clinical investigation.

Read More

Lim to Lead Department of Neurosurgery

Lim to Lead Department of Neurosurgery
Stanford Cancer Institute

Michael Lim, MD, has been appointed chair of the Stanford University School of Medicine’s Department of Neurosurgery. He joined Stanford from the Johns Hopkins University School of Medicine. Dr. Lim succeeds Gary Steinberg, MD, PhD, who is stepping down after 25 years as department chair.

Read More

New Leadership Roles to Focus on Quality and Safety

New Leadership Roles to Focus on Quality and Safety
Sidney Kimmel Cancer Center at Jefferson Health

The Sidney Kimmel Cancer Center at Jefferson Health (SKCC) has announced two leadership roles focused on quality and safety in cancer care. Mark Hurwitz, MD, FASTRO, FACRO, is the new SKCC enterprise cancer quality and safety officer and Valerie Csik, MPH, CPPS, was appointed director of cancer quality and care transformation.

Read More

Chief of Gamma Knife Service Named

Chief of Gamma Knife Service Named
Siteman Cancer Center

Jiayi Huang, MD, has been named chief of the central nervous system/Gamma Knife service at Washington University School of Medicine and Siteman Cancer Center. He had been serving as interim chief since October 2019.

Read More

Population Health Expert Joins Cancer Center

Population Health Expert Joins Cancer Center
The University of Kansas Cancer Center

Elizabeth Calhoun, PhD, MEd, has been named associate dean for population health at the University of Kansas Medical Center. She also joins The University of Kansas Cancer Center’s Cancer Prevention and Control research program.

Read More

Braithwaite Appointed Associate Director for Population Sciences

Braithwaite Appointed Associate Director for Population Sciences
University of Florida Health Cancer Center

Dejana Braithwaite, PhD, has been appointed as associate director for population sciences at the University of Florida Health Cancer Center, starting November 1. Since 2017, she has led the cancer screening group at the Georgetown Lombardi Comprehensive Cancer Center.

Read More

Associate Chief Medical Officer for Radiation Oncology Appointed

Associate Chief Medical Officer for Radiation Oncology Appointed
Yale Cancer Center, Yale School of Medicine

James B. Yu, MD, MHS, has been promoted to associate chief Medical officer for radiation oncology for Smilow Cancer Hospital and Smilow Cancer Hospital Network. Dr. Yu specializes in treating genitourinary cancers.

Read More

Department of Medicine Chair Named

Department of Medicine Chair Named
Wilmot Cancer Institute, UR Medicine

Ruth O’Regan, MD, chief of Hematology, Medical Oncology and Palliative Care at the University of Wisconsin, has been named the next chair of medicine at the University of Rochester Medical Center’s School of Medicine and Dentistry. She succeeds Paul Levy, MD, who is stepping down after a decade as chair.

Read More

Prominent Researchers, Physicians Join Faculty

Prominent Researchers, Physicians Join Faculty
Cedars-Sinai Cancer

Cedars-Sinai Cancer is continuing to expand its clinical and investigative research staff with the addition of several new faculty scientists who bring a breadth of expertise to cancer patients. Dan Theodorescu, MD, PhD, is the center's director.

Read More

Back to News From the Centers

KRAS Inhibitor Sotorasib Appears Safe, Achieves Durable Clinical Benefit in Early Trial

KRAS Inhibitor Sotorasib Appears Safe, Achieves Durable Clinical Benefit in Early Trial
The University of Texas MD Anderson Cancer Center

In a Phase I clinical trial for patients with advanced solid cancers marked by KRAS G12C mutations, the KRAS G12C inhibitor sotorasib (AMG 510) resulted in manageable toxicities and durable clinical benefits. David S. Hong, MD, is lead author on the study.

Read More

Two Million Americans Buy Prescription Drugs Outside the Country

University of Florida Health Cancer Center

Buying prescription drugs from other countries is one way some Americans have coped with rising drug prices. A new University of Florida study finds that 1.5 percent of adults, or more than two million Americans, purchase their prescription drugs from outside the U.S. to save money.

Read More

VICC Leading First Global Study of MDS/MPN Overlap Syndrome

Vanderbilt-Ingram Cancer Center

Overlap syndromes are distinct blood cancers that have features of both myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). The most common of these syndromes is chronic myelomonocytic leukemia. MDS/MPNs are difficult to treat and typically have poor prognoses. Vanderbilt-Ingram Cancer Center is leading the first cooperative international trial for these rare cancers. Michael Savona, MD, is principal investigator.

Read More

Shifting Liver Cancer Cells Away From Migratory State Could Reduce Their Drug Resistance

Fred Hutchinson Cancer Research Center

Whether a liver cancer cell is primed to grow or move affects its ability to resist cancer drugs, according to new work from researchers at Fred Hutchinson Cancer Research Center and the University of Washington. They identified key molecules that orchestrate these different cell states in hepatocellular carcinoma (HCC). In lab dishes, experimental compounds that target these molecules can shift drug-resistant HCC cells toward drug sensitivity.

Read More

Study Highlights Need for Genetic Testing for Patients With Lung Cancer

UK Markey Cancer Center

A study led by researchers at UK Markey Cancer Center highlighted differences in patient diagnosis and treatment in those with non-small cell lung cancer across the state of Kentucky. The study used Kentucky Cancer Registry patient data from 2007-2011 to identify trends in epidermal growth factor receptor (EGFR) mutation testing and the usage of the EGFR inhibitor, erlotinib.

Read More

Study Finds Savings in Blue Cross, Blue Shield Value-Based Primary Care Programs

UAMS Winthrop P. Rockefeller Cancer Institute

Overall health care costs decreased for patients at clinics participating in Arkansas Blue Cross and Shield value-based primary care programs, according to a study by the University of Arkansas for Medical Sciences. The study also found reductions in inpatient stays and use of emergency departments.

Read More

Study Educates Oncologists on LGBTQ+ Health Concerns

Moffitt Cancer Center

Moffitt Cancer Center is launching a nationwide study to help educate oncologists and address health care disparities among LGBTQ+ patients. The study’s findings will inform the groundbreaking COLORS Training Program (Curriculum for Oncologists on LGBTQ+ populations to Optimize Relevance and Skills), which Moffitt developed in 2018.

Read More

Black People More Likely to Die From Colorectal Cancer Spreading to Liver

City of Hope Comprehensive Cancer Center

Analyzing data for about 16,500 advanced colorectal cancer patients, City of Hope researchers found that Black people are more likely than other ethnic groups to die from the disease, especially if it had spread to the liver. They noted that Black people were the least likely to receive chemotherapy and had a 17 percent higher chance of death compared to white people.

Read More

Cancer Cells Take Over Blood Vessels to Spread

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

In laboratory studies, Johns Hopkins Kimmel Cancer Center and Johns Hopkins University researchers observed a key step in how cancer cells metastasize. Trying to determine how groups of cells migrate to other parts of the body, the scientists used tissue engineering to construct a functional 3D blood vessel and grew breast cancer cells nearby.

Read More

NCORP Clinical Trial Accrual Goals Exceeded

The University of Kansas Cancer Center

The University of Kansas Cancer Center’s status as a community site of the National Cancer Institute’s Community Oncology Research Program (NCORP) has been renewed following a successful first year. The cancer center team exceeded clinical trial accrual goals by more than 22 percent.

Read More

Smoking Associated With Worse Outcomes for Bladder Cancer After Surgery

USC Norris Comprehensive Cancer Center

Patients treated for bladder cancer with a surgery known as radical cystectomy have worse outcomes if they are smokers, according to a systematic review and meta-analysis by Keck Medicine of USC. Giovanni Cacciamani, MD, is lead author of the study.

Read More

To Reduce Colorectal Cancer Disparities Among African Americans, More Intervention Research is Needed

Huntsman Cancer Institute, University of Utah

Of any racial group, African-American men have the lowest five-year survival rate for colorectal cancer. A major contributing factor is low adherence to recommended early detection screening, like colonoscopy and home-based stool testing kits. Yet published research on effective strategies to increase screening for this group is minimal.

Read More

Scientists Engineer DNA-based Nanotechnology to Stimulate Potent Antitumor Immune Responses in Preclinical Models

The Wistar Institute

Combining their expertise in protein engineering and synthetic DNA technology, scientists at The Wistar Institute successfully delivered nanoparticle antitumor vaccines that stimulated robust CD8 T cell immunity and controlled melanoma growth in preclinical models. Study results support exploration of this immunotherapy approach for other cancer types.

Read More

Genetic Testing Cost Effective for Newly Diagnosed GIST

UC San Diego Moores Cancer Center

Researchers at Moores Cancer Center at UC San Diego Health have reported that genetic testing is cost-effective and beneficial for newly diagnosed patients with metastatic gastrointestinal stromal tumors (GIST), a type of soft tissue sarcoma that develops in specialized nerve cells in the wall of the digestive system.

Read More

Rubbery Properties Help RNA Nanoparticles Target Tumors Efficiently and Quickly Leave Body

The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

A new study by researchers at OSUCCC – James shows that RNA nanoparticles have elastic and rubbery properties that help explain why these particles target tumors so efficiently and why they possess lower toxicity in animal studies.

Read More

Cancer Discovery Reveals Key Process in Tumor Formation

University of Virginia Cancer Center

A discovery from the University of Virginia School of Medicine may open the door to an entirely new approach to treating cancer: by disrupting a vital condensation process inside cancer cells. Researchers discovered that cancer cells are exceptionally dependent on the proper condensation of a particular protein, AKAP95, during tumor formation. Blocking this process halted the cancer cells in their tracks.

Read More

Combination Immunotherapy Benefits Subset of Patients With Advanced Prostate Cancer

The University of Texas MD Anderson Cancer Center

Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) can generate durable responses in a subset of patients with metastatic castration-resistant prostate cancer (mCRPC), an "immune-cold" cancer that does not typically respond well to immunotherapy.

Read More

Deep Look at Immune Cells in Patient Tumors Reveals Insights on Timing for Treatment Combinations

Roswell Park Comprehensive Cancer Center

Research from a team from Roswell Park Comprehensive Cancer Center explains how radiation helps boost the immune system’s ability to fight cancer in combination with immune checkpoint inhibitors — and provides new evidence that the timing of these therapies can make a big difference in how effectively they work together.

Read More

Investigating Disparities in Eye Cancer Treatment

Stanford Cancer Institute

There are currently two main ways of treating ocular melanoma: radiation therapy or removal of the eye. Prithvi Mruthyunjaya, MD, and Darius Moshfeghi, MD, are investigating whether there are any patterns linking patients' racial, ethnic, or socioeconomic status with which treatment they received and how long they lived after diagnosis.

Read More

Researchers Identify Driver of Further Metastasis in BRAF Inhibitor Resistant Melanoma

Moffitt Cancer Center

Targeted therapy with BRAF-MEK inhibitors is effective against advanced melanoma that cannot be surgically removed or has spread to other areas of the body. However, many patients become resistant to the therapy, often leading to further metastasis. Moffitt Cancer Center researchers who helped develop this type of combination therapy are now working to better understand what leads to this resistance.

Read More

Back to News From the Centers

New Initiative Aims to Put Postponed Cancer Screenings 'Back on the Books'

Prevent Cancer Foundation
To help encourage routine cancer screenings, especially as patients have postponed or canceled them during the COVID-19 pandemic, the Prevent Cancer Foundation has launched a public service announcement campaign, "Back on the Books," to remind people to reschedule their appointments. 

Read More

Winn Part of AACR Congressional Briefing on Cancer Disparities

Winn Part of AACR Congressional Briefing on Cancer Disparities
VCU Massey Cancer Center

As a member of the steering committee that contributed to the American Association of Cancer Research’s inaugural "Cancer Disparities Progress Report," VCU Massey Cancer Center Director Robert Winn, MD, recently participated in a virtual congressional briefing on the report’s findings.

Read More

City of Hope, Chimeric to Develop CAR T Cell Therapy

City of Hope Comprehensive Cancer Center

City of Hope has licensed intellectual property relating to its pioneering chlorotoxin chimeric antigen receptor T cell therapy to Chimeric Therapeutics Limited, an Australian biotechnology company. The center has also dosed its first patient in its innovative chlorotoxin CAR T cell therapy trial.

Read More

Free Genome Sequencing Now Available to All UCSF Patients

UCSF Helen Diller Family Comprehensive Cancer Center

UC San Francisco scientists have launched a precision medicine initiative to offer free voluntary whole genome sequencing to all UCSF Health patients. The goal of the initiative, called the UCSF 3D Health Study (for "Data, Discovery, and Diversity") is to build a genomic database that matches the diversity of UCSF Health’s patient population.

Read More

Innova Therapeutics Receives Rare Pediatric Disease Designation From FDA for Osteosarcoma Treatment

Innova Therapeutics Receives Rare Pediatric Disease Designation From FDA for Osteosarcoma Treatment
Hollings Cancer Center, Medical University of South Carolina

The U.S. Food and Drug Administration (FDA) has granted Innova Therapeutics Inc., rare pediatric disease designation for IVT-8086 for the treatment of osteosarcoma. MUSC Hollings Cancer Center researcher Nancy Klauber-DeMore, MD, was instrumental in the development of the research that led to the therapy.

Read More

Women Surgeons Earn Their Cut of NIH Funding and Then Some

University of Virginia Cancer Center

Women are underrepresented in the field of academic surgery, but women surgeons are earning a disproportionate share of research grants from the National Institutes of Health, a new study has found. Women comprise 19 percent of surgery faculty at academic health systems, but held 26.4 percent of R01 grants, the researchers found.

Read More

Clinical Trial Will Examine Short- and Long-Term Outcomes for Patients With COVID-19 and Cancer

VCU Massey Cancer Center

A nationwide clinical trial funded by the National Cancer Institute and now open at VCU Massey Cancer Center will examine the short- and long-term outcomes of patients with COVID-19 and cancer to gain a more comprehensive understanding of the impacts of infection.

Read More

Back to News From the Centers

Cancer Center Jobs

Clinical Trials Manager
Wilmot Cancer Institute, UR Medicine
Read more
Unit Manager, Experimental Therapeutics Incubator
University of Florida Health Cancer Center
Read more
Associate Director of Finance, Clinical Trials Office
Huntsman Cancer Institute, University of Utah
Read more
Chief, Division of Hematology Oncology
UPMC Hillman Cancer Center
Read more
Clinical Research Regulatory Manager
Holden Comprehensive Cancer Center, University of Iowa
Read more
Director, Biostatistics Shared Resource
Hollings Cancer Center, Medical University of South Carolina
Read more

Meeting Announcements

Artificial Intelligence in Oncology Symposium

October 19, 2020
Virtual Meeting
Hosted by Case Comprehensive Cancer Center

The 2020 Artificial Intelligence in Oncology Symposium: Advancing Science and Policy will bring together experts in AI and machine learning as well as clinical, industry, and federal agency experts in pathology, radiology, drug discovery, and ethics and policy to speak on research developments, regulatory policy, reimbursement and ethics surrounding AI in oncology. For the health and safety of all attendees, this year's symposium will take place virtually.
 
Learn More

2020 SITC Annual Meeting

November 9, 2020
Virtual Meeting
Registration is now open for the Society for Immunotherapy of Cancer’s 35th Anniversary Annual Meeting and Pre-Conference Programs (SITC 2020), a fully virtual experience, taking place online over new dates, November 9-14, 2020. In celebration of the society’s 35th anniversary, all SITC members are invited to register for free. 
Learn More
Back to top